The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers

This study will assess the effect of therapeutic and supratherapeutic plasma exposures of CS‐3150 on the corrected QT (QTc) interval duration after administration of single oral 10‐mg and 40‐mg doses of CS‐3150 in healthy male and female participants. This study will also determine the safety and tolerability of CS‐3150 administration, assess the effect on electrocardiogram (ECG) parameters, detect QT interval (QT)/QTc prolongation with a positive control (moxifloxacin), characterize pharmacokinetics (PK) of CS‐3150, and assess exposure‐response relationship of CS‐3150 on QTc.